# A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

> **NCT03671044** · PHASE3 · RECRUITING · sponsor: **Jina Pharmaceuticals Inc.** · enrollment: 657 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
- **DRUG:** Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
- **DRUG:** Taxotere® (100 mg/m2)

## Key facts

- **NCT ID:** NCT03671044
- **Lead sponsor:** Jina Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-10
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 657 (ESTIMATED)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671044, "A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03671044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*